Human papillomavirus infection: An anonymous prevalence study in South Wales, UK

British Journal of Cancer

Volumn 95, Issue 2, 2006, Pages 226-232

  Hibbitts, S ^a   Rieck, G C ^a   Hart, K ^a   Powell, N G ^a   Beukenholdt, R ^b   Dallimore, N ^c   McRea, J ^d   Hauke, A ^e   Tristram, A ^a   Fiander, A N ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b DARLINGTON MEMORIAL HOSPITAL   (United Kingdom)

^c ROYAL GWENT HOSPITAL   (United Kingdom)

^d LLANDOUGH HOSPITAL   (United Kingdom)

^e Cervical Screening Wales   (United Kingdom)

Author keywords

Cervical cancer; HPV prevalence; HPV vaccine

Indexed keywords

DNA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOLOGY; DISEASE ASSOCIATION; DNA PURIFICATION; ENZYME IMMUNOASSAY; FEMALE; FISHER EXACT TEST; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; INFECTION RISK; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; RISK ASSESSMENT; SCORING SYSTEM; SOCIAL ISOLATION; SOCIOECONOMICS; UNITED KINGDOM; VIRUS IDENTIFICATION; VIRUS INFECTION; VIRUS STRAIN; WART VIRUS;

ADULT; AGE DISTRIBUTION; AGED; ANONYMOUS TESTING; COHORT STUDIES; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SOCIAL CLASS; VAGINAL SMEARS; WALES;

EID: 33745919527     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603245     Document Type: Article

References (33)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802
2. Breslow NE, Day NE (1987) The design and analysis of cohort studies. Statistical Methods in Cancer Research: Volume II IARC Sci Publ (82): 1-406
3. Chan PK, Chang AR, Cheung JL, Chan DP, Xu LY, Tang NL, Cheng AF (2002) Determinants of cervical human papillomavirus infection: differences between high- and low-oncogenic risk types. J Infect Dis 185: 28-35
4. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S, IARC HPV Prevalence Surveys Study Group (2005a) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991-998
5. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM (2005b) Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14: 1157-1164
6. Clifford GM, Smith JS, Aguado T, Franceschi S (2003) Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89: 101-105
7. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, Gilkisson G, McGoogan E (2004) Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 57: 68-72
8. de Sanjose S, Almirall R, Lloveras B, Font R, Diaz M, Munoz N, Catala I, Meijer CJ, Snijders PJ, Herrero R, Bosch FX (2003) Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 30: 788-793
9. de Sanjose S, Bosch FX, Munoz N, Shah K (1997) Social differences in sexual behaviour and cervical cancer. IARC Sci Publ 138: 309-317
10. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757-1765
11. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M (2000) Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92: 464-474
12. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM (1997) A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35: 791-795
13. Krieger N, Quesenberry Jr C, Peng T, Horn-Ross P, Stewart S, Brown S, Swallen K, Guillermo T, Suh D, Alvarez-Martinez L, Ward F (1999) Social class, race/ethnicity, and incidence of breast, cervix, colon, lung, and prostate cancer among Asian, Black, Hispanic, and White residents of the San Francisco Bay Area, 1988-92 (United States). Cancer Causes Control 10: 525-537
14. McFadden K, McConnell D, Salmond C, Crampton P, Fraser J (2004) Socioeconomic deprivation and the incidence of cervical cancer in New Zealand: 1988-1998. N Z Med J 117: U1172
15. Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M, Franceschi S, Meijer CJ, Arslan A, Munoz N, HPV Study Group HPV Study (2002) Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 87: 324-333
16. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2003) Epidemiologic classfication of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527
17. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111: 278-285
18. Murphy M, Goldblatt P, Thornton-Jones H, Silcocks P (1990) Survival among women with cancer of the uterine cervix: influence of marital status and social class. J Epidemiol Commun Health 44: 293-296
19. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Jaspars LH, Voorhorst FJ, Verheijen RH, Meijer CJ (2002) Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol 55(6): 435-439
20. Parazzini F, Chatenoud L, La Vecchia C, Negri E, Franceschi S, Bolis G (1998) Determinants of risk of invasive cervical cancer in young women. Br J Cancer 77: 838-841
21. Parikh S, Brennan P, Boffetta P (2003) Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 105: 687-691
22. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108
23. Petignat P, Faltin D, Goffin F, Billieux MH, Stucki D, Sporri S, Vassilakos P (2005) Age-related performance of human papillomavirus testing used as an adjunct to cytology for cervical carcinoma screening in a population with a low incidence of cervical carcinoma. Cancer 105: 126-132
24. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M, Elanko N, Coleman D, Yule R, Desai M (2004) Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 91: 942-953
25. Ronco G, Ghisetti V, Segnan N, Snijders PJ, Gillio-Tos A, Meijer CJ, Merletti F, Franceschi S (2005) Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer 41: 297-305
26. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, Stanton CK, Manos MM (1993) Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85: 958-964
27. Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH (2004) Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 10: 2954-2961
28. Sweetnam P, Evans DM, Hibbard BM, Jones JM (1981) The Cardiff Cervical Cytology Study. Prevalence and epidemiology of cervical neoplasia. J Epidemiol Commun Health 35: 83-90
29. Thomas DB, Qin Q, Kuypers J, Kiviat N, Ashley RL, Koetsawang A, Ray RM, Koetsawang S (2001) Human papillomaviruses and cervical cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell cervical carcinomas. Am J Epidemiol 153: 732-739
30. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6: 271-278
31. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19
32. Wall SR, Scherf CF, Morison L, Hart KW, West B, Ekpo G, Fiander AN, Man S, Gelder CM, Walraven G, Borysiewicz LK (2005) Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. Br J Cancer 93: 1068-1076
33. Waterhouse J (2003) The European Standard Population (Annex 5). World Health Annual of Statistics. Cancer Incidence in Five Continents. Lyon: IARC WHO1976 3: 456